
ESSA Pharma appoints independent director
pharmafile | March 9, 2015 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |Â Â essa pharma, franklin bergerÂ
US pharma development firm ESSA Pharma has appointed Franklin Berger as an independent director.
A resident of New York, Berger’s background includes strategic advisory work with venture capital firms and international biopharma companies. Most recently he was a managing director for US Equity Research at J. P. Morgan Securities (JPM) from 1998 to 2003.
During his five years at JPM he was involved with the issuance of over $12 billion in biotechnology company equity or equity-linked securities. He has been associated with several financings in the biotech sector including the Genentech initial public offering, the first large Celgene Corporation financings as well as many firms in their rapid growth phase.
Berger began his career as a sell-side analyst at Josephthal & Co. in 1991, subsequently moving to Salomon Smith Barney in 1997 serving as director, equity research and senior biotechnology analyst.
“We are delighted to have Franklin join our board,” says Richard Glickman, chairman of the ESSA board of directors. “As an investor in ESSA, he has a serious stake in our success. As a deeply experienced strategic advisor, he will bring an invaluable perspective to our strategy decisions.”






